Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Teja Thorat"'
Publikováno v:
BMJ Open Respiratory Research, Vol 11, Iss 1 (2024)
Background Ivacaftor approval was extended to people with cystic fibrosis (CF) with ≥1 of 28 additional ivacaftor-responsive mutations in the USA in 2017 based on preclinical in vitro data. This retrospective, observational study assessed real-worl
Externí odkaz:
https://doaj.org/article/9a3098e851c643669ab5bcc75b86c423
Autor:
Jamie Duckers, Beth Lesher, Teja Thorat, Eleanor Lucas, Lisa J. McGarry, Keval Chandarana, Fosca De Iorio
Publikováno v:
Journal of Clinical Medicine, Vol 10, Iss 7, p 1527 (2021)
Cystic fibrosis (CF) is a rare, progressive, multi-organ genetic disease. Ivacaftor, a small-molecule CF transmembrane conductance regulator modulator, was the first medication to treat the underlying cause of CF. Since its approval, real-world clini
Externí odkaz:
https://doaj.org/article/8397b4b4534a4c428fce6e1a4f8cc9b9
Autor:
Alyssa Bilinski, Peter Neumann, Joshua Cohen, Teja Thorat, Katherine McDaniel, Joshua A Salomon
Publikováno v:
PLoS Medicine, Vol 14, Iss 10, p e1002397 (2017)
Potential cost-effective barriers in cost-effectiveness studies mean that budgetary impact analyses should also be included in post-2015 Sustainable Development Goal projects says Joshua Salomon and colleagues.
Externí odkaz:
https://doaj.org/article/f272336fa3cc452f9cb9660f4e3e8585
Autor:
Peter J Neumann, Teja Thorat, Yue Zhong, Jordan Anderson, Megan Farquhar, Mark Salem, Eileen Sandberg, Cayla J Saret, Colby Wilkinson, Joshua T Cohen
Publikováno v:
PLoS ONE, Vol 11, Iss 12, p e0168512 (2016)
Calculating the cost per disability-adjusted life years (DALYs) averted associated with interventions is an increasing popular means of assessing the cost-effectiveness of strategies to improve population health. However, there has been no systematic
Externí odkaz:
https://doaj.org/article/a5b826284e4a4ae7ba9d0c951d698784
Autor:
Rodrigo Athanazio, Luiz Vicente da Silva Filho, Rodolfo Leão Borges, Alessandro Bigoni, Ramon Pereira, Paula Cristina Pungartnik, Suelen Silva, Krishan Mistry, Vasilis Nikolaou, Luciana Tarbes Mattana Saturnino, Teja Thorat
Publikováno v:
Brasília Médica. 60
Autor:
Nicholas J. Simmonds, C. Kors van der Ent, Carla Colombo, Nils Kinnman, Cynthia DeSouza, Teja Thorat, Marci L. Chew, Keval Chandarana, Carlo Castellani
Publikováno v:
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
VOCAL was an observational study of the effect of long-term ivacaftor on real-world clinical outcomes and healthcare resource utilization (HCRU) in people with cystic fibrosis (pwCF) in Italy, the Netherlands, and the UK.pwCF aged ≥6 years with non
Autor:
N. Kinnman, M Chew, K van der Ent, Keval Chandarana, Carlo Castellani, Teja Thorat, Nicholas J. Simmonds, Carla Colombo, C DeSouza
Publikováno v:
Treatment choices in cystic fibrosis and bronchiectasis: what works and when.
Autor:
Keval Chandarana, Nicholas J. Simmonds, Carlo Castellani, Carla Colombo, K van der Ent, N. Kinnman, Teja Thorat, C DeSouza
Publikováno v:
Treatment choices in cystic fibrosis and bronchiectasis: what works and when.
Autor:
Kors Van Der Ent, Carlo Castellani, C DeSouza, Teja Thorat, N. Kinnman, Carla Colombo, Nicholas J. Simmonds, Keval Chandarana
Publikováno v:
Paediatric cystic fibrosis (CF).
Autor:
Brendan Limone, Machaon Bonafede, Jaime L. Rubin, Michael W. Konstan, Krutika Jariwala-Parikh, Teja Thorat, Lisa J McGarry
Publikováno v:
Pediatric Pulmonology
Background Adverse health impacts of cystic fibrosis (CF) can be present in children before respiratory complications are observed. Children with CF show progressive health decline, with increasing lung function decline in adolescence. This study aim